Amylin Pharmaceuticals, Inc.

Astrazeneca Pharmaceuticals LP

Duo Security, Inc.

Chemocentryx, Inc.

Other

The Brigham and Women's Hospital, Inc.

Resolvyx Pharmacuticals, Inc.

Resolvyx Pharmaceuticals, Inc.

Michael R Hanley

David Geoffrey Parkes

Christine Marie Mack

Soumitra S Ghosh

Christopher Joseph Soares

Carolyn M Jodka

Diana Y Lewis

Odile Esther Levy

Lawrence J D'Souza

Andrew A Young

Jon Oberheide

Alain D Baron

Mary Erickson

Richard A Pittner

Ved Srivastava

Samuel Janssen

Thomas J Schall

Daniel J Dairaghi

Zhenhua Miao

Jennifa Gosling

Adam P Goodman

Peter M Johnson

Omar Abduljaber

James Leslie Barclay

Kevin D Laugero

Thao Le

Charles Nicholas Serhan

Kathryn Susan Prickett

Qing Lin

Dale John Talbot

Daniel W Goodman

Behrouz Bruce Forood

Stuart L Bursten

Kyle Lady

Olabode Anise

Paul McGonigle

Lawrence J D'souza

Lawrence D'SOUZA

Soumitra G Ghosh

Diana Yvonne Lewis

Carolyn Marie Jodka

A system and method for mitigating security vulnerabilities of a computer network by detecting a management status of an endpoint computing device attempting to authenticate to one or more computing resources accessible via the computer network includes: detecting an authentication attempt by the endpoint computing device to the computer network; during the authentication attempt, collecting management status indicia from the endpoint computing device, wherein the management status indicia comprise data used to determine a management status of the endpoint computing device; using the management status indicia to identify the management status of the endpoint computing device and identifying the management status of the endpoint computing device; and controlling access to the computer network based on (a) whether the authentication attempt by the endpoint computing device is successful and (b) the identified management status of the endpoint computing device.

Systems and methods for endpoint management

Systems and methods are provided that include: accessing implicit authentication data from a possession factor associated with an authorized user; at the possession factor or at an authentication platform: generating a possession confidence level using the implicit authentication data, the possession confidence level being one of a plurality of possession confidence levels, the possession confidence level indicating a likelihood that the possession factor is possessed by the authorized user; identifying, among a plurality of varying authentication requirements, an authentication requirement for the transaction based on the possession confidence level, the authentication requirement defines a process or action to prove authority to perform the transaction or a process or action to prove an identity of a user attempting to perform the transaction; and implementing the authentication requirement for the transaction.

Method for automatic possession-factor authentication

Systems and methods for endpoint management classification

A system and method that enables the configuration of computer security of a subject entity at a computer security platform includes collecting a corpus of security data relating to one or more security configurations of the network maintained by the subject entity, analyzing the corpus of security data to determine one or more vulnerability factors and one or more security behaviors relating to the subject entity, generating a security assessment for the subject entity based on the analysis of the corpus of security data, generating a computer security policy for the security environment based on the security assessment, and providing, to the subject entity, a security policy recommendation incorporating at least a subset of the generated computer security policy.

Systems and methods for intelligently configuring computer security

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Hybrid polypeptides with selectable properties

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

GIP analog and hybrid polypeptides with selectable properties

GIP and exendin hybrid polypeptides

The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.

Methods for treatment using amylin family peptides

The present invention discloses an adjustable medication blister package that provides custom patient schedule of medications based on a future exam time. The adjustable medication blister package has multiple medications individually enclosed in blister packs where each blister pack is indicated with correct time to take each medication. A timing indicator which is populated with times is placed behind a base card where individual correct times can be seen through indicator apertures once a user selects the time of the future event using an adjustable time selector.

Medication dispensing blister card package with adjustable mechanism that provides a custom patient schedule for complex medication regimens

DPP-IV resistant GIP hybrid polypeptides with selectable properties

Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.

Amylin and amylin agonists for treating psychiatric diseases and disorders

Growing community of inventors

Corte Madera, CA, United States of America

Michael R Hanley